Sandoz to Acquire Cimerli Business from Coherus for $170 Million

By David Sachs

Sandoz will buy vision-impairment drug Cimerli from Coherus BioSciences for $170 million.

The Swiss pharmaceutical company said Monday that the purchase of the U.S. company's medication includes a biologics license, product inventory, and ophthalmology sales, as well as access to proprietary commercial software.

The medication, which treats serious eye conditions including macular degeneration, is interchangeable with Lucentis, a drug developed by Genentech. Sandoz expects to close the deal in the second half of this year.

Write to David Sachs at [e-mail]

(END) Dow Jones Newswires

01-22-24 0144ET